Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial.
COPD
chronic mucus hypersecretion
chronic obstructive pulmonary disease
clinical outcomes
single-inhaler triple therapy
Journal
Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
16
02
2022
accepted:
18
07
2022
pubmed:
16
8
2022
medline:
22
11
2022
entrez:
15
8
2022
Statut:
ppublish
Résumé
Chronic mucus hypersecretion (CMH) is a clinical phenotype of COPD. This exploratory post hoc analysis assessed relationship between CMH status and treatment response in IMPACT. Patients were randomized to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg, FF/VI 100/25 μg or UMEC/VI 62.5/25 μg and designated CMH+ if they scored 1/2 in St George's Respiratory Questionnaire (SGRQ) questions 1 and 2. Endpoints assessed by baseline CMH status included on-treatment exacerbation rates, change from baseline in trough forced expiratory volume in 1 second, SGRQ total score, COPD Assessment Test (CAT) score, proportion of SGRQ and CAT responders at Week 52 and safety. Of 10,355 patients in the intent-to-treat population, 10,250 reported baseline SGRQ data (CMH+: 62% [n = 6383]). FF/UMEC/VI significantly (p < 0.001) reduced on-treatment moderate/severe exacerbation rates versus FF/VI and UMEC/VI in CMH+ (rate ratio: 0.87 and 0.72) and CMH- patients (0.82 and 0.80). FF/UMEC/VI significantly (p < 0.05) reduced on-treatment severe exacerbation rates versus UMEC/VI in CMH+ (0.62) and CMH- (0.74) subgroups. Similar improvements in health status and lung function with FF/UMEC/VI were observed, regardless of CMH status. In CMH+ patients, FF/VI significantly (p < 0.001) reduced on-treatment moderate/severe and severe exacerbation rates versus UMEC/VI (0.83 and 0.70). FF/UMEC/VI had a favourable benefit: risk profile versus dual therapies irrespective of CMH status. The presence of CMH did not influence treatment response or exacerbations, lung function and/or health status. However, CMH did generate differences when dual therapies were compared and the impact of CMH should be considered in future trial design.
Sections du résumé
BACKGROUND AND OBJECTIVE
Chronic mucus hypersecretion (CMH) is a clinical phenotype of COPD. This exploratory post hoc analysis assessed relationship between CMH status and treatment response in IMPACT.
METHODS
Patients were randomized to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg, FF/VI 100/25 μg or UMEC/VI 62.5/25 μg and designated CMH+ if they scored 1/2 in St George's Respiratory Questionnaire (SGRQ) questions 1 and 2. Endpoints assessed by baseline CMH status included on-treatment exacerbation rates, change from baseline in trough forced expiratory volume in 1 second, SGRQ total score, COPD Assessment Test (CAT) score, proportion of SGRQ and CAT responders at Week 52 and safety.
RESULTS
Of 10,355 patients in the intent-to-treat population, 10,250 reported baseline SGRQ data (CMH+: 62% [n = 6383]). FF/UMEC/VI significantly (p < 0.001) reduced on-treatment moderate/severe exacerbation rates versus FF/VI and UMEC/VI in CMH+ (rate ratio: 0.87 and 0.72) and CMH- patients (0.82 and 0.80). FF/UMEC/VI significantly (p < 0.05) reduced on-treatment severe exacerbation rates versus UMEC/VI in CMH+ (0.62) and CMH- (0.74) subgroups. Similar improvements in health status and lung function with FF/UMEC/VI were observed, regardless of CMH status. In CMH+ patients, FF/VI significantly (p < 0.001) reduced on-treatment moderate/severe and severe exacerbation rates versus UMEC/VI (0.83 and 0.70).
CONCLUSION
FF/UMEC/VI had a favourable benefit: risk profile versus dual therapies irrespective of CMH status. The presence of CMH did not influence treatment response or exacerbations, lung function and/or health status. However, CMH did generate differences when dual therapies were compared and the impact of CMH should be considered in future trial design.
Identifiants
pubmed: 35970518
doi: 10.1111/resp.14339
pmc: PMC9804213
doi:
Substances chimiques
Bronchodilator Agents
0
vilanterol
028LZY775B
Fluticasone
CUT2W21N7U
Drug Combinations
0
Androstadienes
0
Banques de données
ClinicalTrials.gov
['NCT02164513']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1034-1044Subventions
Organisme : Department of Health
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
Références
Lancet. 1965 Apr 10;1(7389):775-9
pubmed: 4165081
Respirology. 2022 Dec;27(12):1034-1044
pubmed: 35970518
Lancet Respir Med. 2015 Jun;3(6):435-42
pubmed: 25878028
Eur Respir J. 2012 Jul;40(1):28-36
pubmed: 22282547
Eur Respir J. 2016 Aug;48(2):320-30
pubmed: 27418551
Am J Respir Crit Care Med. 1996 Jan;153(1):3-50
pubmed: 8542133
Ann Am Thorac Soc. 2015 Mar;12(3):332-9
pubmed: 25575351
Int J Occup Med Environ Health. 2014 Jan;27(1):50-9
pubmed: 24464442
Expert Rev Respir Med. 2021 Jan;15(1):27-37
pubmed: 32730716
Am J Respir Crit Care Med. 1996 May;153(5):1530-5
pubmed: 8630597
Lancet Respir Med. 2019 Sep;7(9):745-756
pubmed: 31281061
Chest. 2019 Feb;155(2):266-271
pubmed: 30080996
Curr Opin Pulm Med. 2015 Mar;21(2):133-41
pubmed: 25575367
N Engl J Med. 2018 May 03;378(18):1671-1680
pubmed: 29668352
Int J Chron Obstruct Pulmon Dis. 2014 Jan 24;9:139-50
pubmed: 24493923
Int J Chron Obstruct Pulmon Dis. 2020 Oct 13;15:2467-2476
pubmed: 33116463
Am J Respir Crit Care Med. 2016 Mar 15;193(6):662-72
pubmed: 26695373
Respir Res. 2011 Jan 27;12:18
pubmed: 21272339
Eur Respir J. 2018 Jan 18;51(1):
pubmed: 29348179
Chest. 2011 Sep;140(3):626-633
pubmed: 21474571
Chest. 2009 Apr;135(4):975-982
pubmed: 19017866
Lancet. 2017 May 13;389(10082):1919-1929
pubmed: 28385353
Am Rev Respir Dis. 1992 Jun;145(6):1321-7
pubmed: 1595997
Respir Med. 2014 Dec;108(12):1761-70
pubmed: 25459449
Chest. 2019 Oct;156(4):685-695
pubmed: 31047955
J Transl Int Med. 2015 Jun-Sep;3(3):89-92
pubmed: 27847895
PLoS One. 2015 Dec 10;10(12):e0143793
pubmed: 26659582
Respir Med. 2014 Oct;108(10):1469-80
pubmed: 25154699